Pfizer's Sasanlimab Hits Late-Stage Study Primary Endpoint for Bladder Cancer
Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...
Pfizer's bladder cancer therapy meets main goal in late-stage study
The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study ...